Dr Reddy’s launches two new semaglutide brands amid Obeda supply disruptions

The drugmaker has shifted production to a partner facility and expects to resolve the impurity issue affecting its injectable product next month.

NewsBeagle is a discovery engine. We show the headline, a short source-supplied summary and clear attribution. The complete reporting remains with the publisher.